English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45346/58522 (77%)
造訪人次 : 2505105      線上人數 : 272
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/62902


    題名: 金剛纂之抗癌及抗發炎活性成分研究
    Studies on the anti-cancer and anti-inflammatory constituents of Euphorbia neriifolia
    作者: 張世霖
    CHANG, STEPHEN S.
    貢獻者: 中草藥臨床藥物研發博士學位學程
    林良宗
    戴承杰
    郭曜豪
    關鍵詞: 金剛纂;火巷;甘遂烷型三?;大戟烷型三?;甲基柔花酸衍生物;抗發炎反應;細胞凋亡;細胞毒殺
    Euphorbia neriifolia;Euphorbiace;Tirucallanes;Euphanes;Methylellagicacid derivatives;Anti-inflammatory;Apoptosis;Cytotoxic
    日期: 2023-07-12
    上傳時間: 2023-09-22 13:51:40 (UTC+8)
    摘要: 金剛纂(火巷,Euphorbia neriifolia Linn) 廣泛分佈於亞洲,在民間醫學中常用於治療與炎症、糖尿病和癌症等等相關的疾病。從金剛纂莖的乙醇萃取二氯甲烷層中分離出十四個未曾報告過6/6/6/5四環三?化合物,包括十二個大戟烷型(Euphane type)四環三?化合物Neritriterpenols A-B、Neritriterpenols D-H和Neritriterpenols J-N等,以及兩個甘遂烷型(Tirucallane type)四環三?化合物Neritriterpenol C和 Neritriterpenol I,另外從乙酸乙酯層中首次分離出三個已知的甲基鞣花酸衍生物:分別為3,3',4-tri-O-methyl-4'-O-rutinosyl ellagic acid、3,3'-di-O-methylellagic acid、和 3,3',4'-tri-O-methyl ellagicacid。使用 MTT測定,結果表明,在甲基鞣花酸衍生物處理48小時後對A549和MCF-7細胞顯示出更有效的抑制作用。此外,3,3',4'-tri-O-methylellagic acid對A549 和MCF-7細胞顯示隨劑量增加導致晚期細胞凋亡更顯著分別為97%與93%。結果指出Neritriterpenols A-G三?類化合物在人類肺癌、結腸腺癌、乳腺癌和肝細胞癌中具有抗癌活性。初步SAR研究表明甘遂 烷型和大戟烷型三?類化合物在C17的側鏈上含有雙鍵或不飽和基團,會促進生物活性和加強抗癌效用。透過測量 Neritriterpenols H-N 對IL-6和TNF-α抗炎活性的抑制作用。有趣的是,Neritriterpenol H 與 Neritriterpenols J-N 對LPS誘導的IL-6表現出選擇抑制作用,Neritriterpenol I 表現出對IL-6和TNF-α抑制作用。顯示金剛纂的萃取物,具有抗發炎活性以及抑制癌症細胞株A549、MCF-7和Hep G2細胞生長及造成細胞凋亡,並通過Caspase實驗,會經由caspase-9誘導的粒線體裂變參與細胞凋亡機轉,可有效的抑制腫瘤生長並能誘導細胞株造成的凋亡現象,以達到調節保護功能。
    Euphorbia neriifolia L., is widely distributed in Asia and commonly used in folk medicine to treat ailments related to inflammation, diabetes, and canc er, among others. Fourteen previously unreported 6/6/6/5 tetracyclic triter penoids were isolated from the ethanol-extracted dichloromethane layer of E. neriifolia stem, including twelve euphane type triterpenoids for Neritriter penols A-B, Neritriterpenols D-H and Neritriterpenols J-N, and two tirucallane type triterpenols Neritriterpenol C and Neritriterpenol I, in addition to three known methyl ellagic acid derivatives: 3,3',4-tri-O-methyl-4'-O-rutinosyl ellagic acid, 3,3'-di-O-methylellagic acid, and 3,3',4'-tri-O-methyl ellagic acid. Using the MTT assay, it was shown that methyl ellagic acid derivatives showed more potent inhibitory effects on A549 and MCF-7 cells after 48 hours of treatment. In addition, 3,3',4'-tri-O-methylellagic acid on A549 and MCF-7 cells showed that the dose-increased lead to late cell apoptosis was more significant, 97% and 93%, respectively. The results indicate that Neritriterpenols A-G triterpenoids have anti-cancer activity in human lung, colon adenocarcinoma, breast and hepatocellular carcinoma. Preliminary SAR studies have shown those triterpenoids contain double bonds or unsaturated groups on the side chain of C17, which will promote biological activity and enhance anti-cancer effects. Inhibition of IL-6 and TNF-α anti-inflammatory activity. Interestingly, Neritriterpenol H and Neritriterpenols J-N showed selective inhibition of IL-6. Neritriterpenol I showed inhibition of IL-6 and TNF-α. E. neriifolia extracts shown with anti-inflammatory activity and inhibits the growth and apoptosis of cancer cell lines A549, MCF-7 and Hep G2 cells. Through the Caspase experiment, it will participate in apoptosis through mitochondrial fission induced by caspase-9 which can effectively inhibit tumor growth and induce apoptosis caused by cell lines, so as to achieve the regulation and protection function.
    描述: 博士
    指導教授:林良宗
    共同指導教授:戴承杰
    共同指導教授:郭曜豪
    委員:王靜瓊
    委員:李慶國
    委員:林良宗
    委員:林若凱
    委員:陳俊憲
    委員:郭曜豪
    委員:戴承杰
    資料類型: thesis
    顯示於類別:[中草藥臨床藥物研發博士學位學程] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML91檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋